Ones To Watch News
Refine Search
Biotechnology
Privately-held immunotherapy company Inmagene Biopharmaceuticals is taking over Ikena Oncology in a reverse merger deal, forming a new company, InmageneBio. 27 December 2024
Biotechnology
California’s AusperBio Therapeutics has secured $73 million in series B financing to propel its lead candidate, AHB-137, an antisense oligonucleotide therapy. 27 December 2024
Pharmaceutical
USA-based clinical-stage biopharma Traws Pharma saw its shares leap more than 150% to $12.57 as it announced progress in the development of its investigational one-dose influenza (flu) investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. 24 December 2024
Biotechnology
Texan biopharma firm XBiotech has announced a suspension of its clinical program in rheumatology, after its Phase II trial for rheumatoid arthritis failed to meet the primary endpoint. 23 December 2024
Pharmaceutical
New York-based Nuvation Bio today announced that the FDA has accepted the company’s new drug application (NDA) for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) for the treatment of advanced ROS1+ NSCLC (line agnostic), for priority review. 23 December 2024
Pharmaceutical
French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience in pneumococcal vaccines, with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations. 23 December 2024
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Shares of specialty drugmaker BioDelivery Sciences International shot up 52% to $3.64 in pre-market trading today, after it agreed to be acquired by fellow USA-based Collegium Pharmaceuticals. 14 February 2022
Biotechnology
The US Food and Drug Administration (FDA) has blocked attempts to halt trials of Cassava Sciences’ experimental Alzheimer’s drug simufilam. 14 February 2022
Pharmaceutical
Shares of Bavarian Nordic were down 3.7% at 164.55 Danish kroner by late morning today, despite announcing that the US Food and Drug Administration has granted Breakthrough Therapy designation for the Danish company's vaccine candidate, MVA-BN RSV, for active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or older. 14 February 2022
Biotechnology
Dutch rare diseases biotech firm ProQR Therapeutics saw its shares plummet more than 74% to $1.45 today, as it announced that its pivotal Phase II/III Illuminate trial of sepofarsen for the treatment of CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of best corrected visual acuity (BCVA) at Month 12. 11 February 2022
Biotechnology
A biotech company called Seismic Therapeutic has launched with the aim of advancing machine learning for immunology drug development. 10 February 2022
Biotechnology
US biotech firm Ventus Therapeutics, which is developing small molecule therapeutics across a broad range of disease indications, announced today the closing of a $140 million Series C financing. 9 February 2022
Biotechnology
UK-headquartered pharma services and products company Clinigen Group announced it has signed a distribution agreement, with USA-based Deciphera Pharmaceuticals for the supply and distribution of Qinlock (ripretinib) into multiple countries across the globe. 9 February 2022
Biotechnology
German biopharmaceutical contract development and manufacturing organization (CDMO AGC Biologics has expanded its partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, Comirnaty, at the company’s Heidelberg facility. 9 February 2022
Biotechnology
French biotech MaaT Pharma has entered into a partnership agreement with contract development and manufacturing organization (CDMO) Skyepharma to build what to date will be France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based therapeutics. 9 February 2022
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics saw its shares plunge nearly 23% to $7.93 by mid-morning, despite the company releasing a bullish statement on a new trial of its already marketed drug Nexpovio/Xpovio (selinexor) as a treatment for endometrial cancer. 8 February 2022
Biotechnology
Biomunex Pharmaceuticals, a privately-held French biotech focused on providing immuno-therapeutics, and Institut Curie, France’s leading cancer center, today announce a new chapter in their strategic research collaboration. 7 February 2022
Pharmaceutical
The Russian drugmaker Pharmasyntez-Nord is finishing preparations for the commissioning of a second stage of its large-scale production facility in St Petersburg. 7 February 2022
Biotechnology
UK and USA-based biotech firm Orchard Therapeutics’ shares closed up 7.6% and rose a further 4.4% to $1.18 in after-hours trading on Friday, after the company gained clearance for Nation Health Service use in England and Wales for its stem cell therapy Libmeldy (atidarsagene autotemcel). 5 February 2022
Biotechnology
US biopharma firm Mersana Therapeutics’ shot up 9% to $4.67 in early trading, after it announced a research collaboration and license agreement with Janssen Biotech, a part of healthcare giant Johnson & Johnson, to discover novel antibody drug conjugates (ADCs) for three targets. 3 February 2022
Biotechnology
Having been a prolific buyer and licensor of medicines, investigational candidates and companies, including its $64 billion acquisition of Shire in 2018, Japanese drug major Takeda Pharmaceutical is also spinning out assets, some into a newly-formed companies such as Ensoma. 1 February 2022
Biotechnology
Shares of Ionis Pharmaceuticals dropped a relatively modest 5.3% to $30.00 in early trading, as its partner US pharma giant Pfizer said it was pulling out of their collaboration on the ANGPTL3 protein-targeting drug vupanorsen. 31 January 2022
Biotechnology
French biotech Tollys, which is developing the first anti-cancer immunotherapy based on a synthetic Toll-Like Receptor 3 (TLR3) specific agonist, today announces that it has renewed and extended its research collaboration started in 2020 with an unnamed pharmaceutical company, described as “a leader in immuno-oncology.” 31 January 2022
Biotechnology
London-listed Irish infectious diseases specialist Poolbeg Pharma today confirmed that it has signed the licence deal for AnaBio Technologies’ microencapsulation and nanoencapsulation technologies to develop an oral vaccine delivery platform. 31 January 2022
Biotechnology
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
Pharmaceutical
French ophthalmology specialist Laboratoires Théa has signed an agreement to purchase seven branded ophthalmic products from Akorn Operating Company. 31 January 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze